Oral MS drug BG-12 significantly reduced MS relapses

Discuss Tecfidera (BG-12, dimethyl fumarate) as an oral treatment for multiple sclerosis.

Oral MS drug BG-12 significantly reduced MS relapses

Postby MSUK » Thu Oct 20, 2011 11:43 pm

Oral MS drug BG-12 significantly reduced MS relapses and disability progression

Image

Biogen Idec BIIB today announced positive data from the Phase 3 DEFINE clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS).

Results showed that 240 mg of BG-12, administered either twice a day (BID) or three times a day (TID), significantly reduced the proportion of patients who relapsed by 49 percent and 50 percent, respectively, at two years compared with placebo.

Detailed data from DEFINE will be presented at the 5th Joint Triennial Congress of the European and Americas Committees on Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS) in Amsterdam, including a platform presentation on Friday, October 21, 2011 at 9:30 a.m. CEST.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1679
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2211
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Re: Oral MS drug BG-12 significantly reduced MS relapses

Postby Vikingquest » Fri Oct 21, 2011 11:52 am

This is great news, no? When will it be available in the UK?
User avatar
Vikingquest
Family Member
 
Posts: 86
Joined: Mon Jul 04, 2011 2:00 pm


Return to Tecfidera (BG-12, dimethyl fumarate)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service